Moderate to Severe Thrombocytopenia and Survival Predictors in Pregnant Women  During the Post-COVID-19 Pandemic ERA

Sofia Naz; Islam Bano; Munnaza  Andleeb; Zahra  Waseem; Zoha  Nisar

doi:10.51253/pafmj.v74i3.10587

Authors

Sofia Naz Department of Gynae & Obs, Quetta Institute of Medical Sciences/Combined Military Hospital Quetta /National University of Medical Sciences (NUMS) Pakistan
Islam Bano Department of Gynae & Obs, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Munnaza Andleeb Department of Gynae & Obs, Quetta Institute of Medical Sciences/Combined Military Hospital Quetta /National University of Medical Sciences (NUMS) Pakistan
Zahra Waseem Department of Gynae & Obs, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Zoha Nisar Department of Gynae & Obs, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i3.10587

Keywords:

COVID-19 vaccines, COVID-19 infection during pregnancy, Gestational thrombocytopenia, Post-COVID-19 autoimmune phenomenon.

Abstract

Objective: To determine the moderate to severe thrombocytopenia (platelet count ≤100,000/ml) in pregnant women during routine follow-up visits and assess the associated risk of maternal death.

Study Design: Cross-sectional study.

Place and Duration of Study: Combined Military Hospital Rawalpindi and Combined Military Hospital, Quetta Pakistan, from May to Dec 2022.

Methodology: The study included ninety-four pregnant women who had a history of COVID-19 infection in their current pregnancy or in the past, had been vaccinated against the Sars-CoV-2 virus, and had a platelet count of less than 100,000/mL. Regression analysis was used to determine whether variables were significant predictors of survival, and appropriate statistical tests were used to evaluate significant relationships.

Results: During the study period, 2,104 patients gave birth vaginally or by caesarean section. For this duration, the frequency of pregnant women with platelet counts below 100,000/ml was calculated at 4.47%. Only four of the 94 patients died. Potential survival predictors identified were hemoglobin level, COVID-19 infection history, and COVID-19 infection during the current pregnancy.

Conclusions: The frequency of patients with moderate to severe thrombocytopenia has increased from 1% to 4.47 percent in the post-COVID-19 pandemic era. Pregnant women with moderate to severe thrombocytopenia have significant predictors of survival, including a history of COVID-19 infection, current COVID-19 infection, and haemoglobin levels.

Downloads

Download data is not yet available.

References

Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology 2022; 165(4): 386-401.

https://doi.org/10.1111/imm.13443

Parums DV. Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). Med Sci Monit 2021; 27: e932899. https://doi.org/10.12659/MSM.932899

Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. JAMA Cardiol 2021; 6(10): 1202-1206.

https://doi.org/10.1001/jamacardio.2021.2833

Román GC, Gracia F, Torres A, Palacios A, Gracia K, Harris, D. Acute Transverse Myelitis (ATM): Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222). Front Immunol 2021; 12: 653786.

https://doi.org/10.3389/fimmu.2021.653786

Moses ML, Kazzi NG, Lee L. Severe thrombocytopenia in a pregnant patient with asymptomatic COVID-19 infection: a case report. Cureus 2021; 13(1): e12904.

https://doi.org/10.7759/cureus.12990

Kadir RA, Kobayashi T, Iba T, Erez O, Thachil J, Kazi S, et al. COVID‐19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry—Communication from the ISTH SSC for Women’s Health. J Thromb Haemost 2020; 18(11): 3086-3098.

https://doi.org/10.1111/jth.15072

Barsode S, Tarlekar V, Shora M, Mehendale S. Clinical profile of thrombocytopenia in pregnancy. Indian J ObstetGynecol Res 2019; 6(2): 192-195. http://doi.org/10.18231/j.ijogr.2019.044

Reese JA, Peck JD, Deschamps DR, McIntosh JJ, Knudtson EJ, Terrell DR, et al. Platelet counts during pregnancy. N Engl J Med 2018; 379(1): 32-43. http://doi.org/10.1056/NEJMoa1802897

Rabaan AA, Bakhrebah MA, Mutair AA, Alhumaid S, Al-Jishi JM, AlSihati J, et al. Systematic review on pathophysiological complications in severe COVID-19 among the non-vaccinated and vaccinated population. Vaccines 2022; 10(7): 985.

https://doi.org/10.3390/vaccines10070985

Islam A, Bashir MS, Joyce K, Rashid H, Laher I, Elshazly S. An update on COVID-19 vaccine induced thrombotic throm-bocytopenia syndrome and some management recom-mendations. Molecules 2021; 26(16): 5004.

https://doi.org/10.3390/molecules26165004

Greinacher A, Langer F, Makris M, Pai M, Pavord S, Tran H, et al. Vaccine‐induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources. J Thromb Haemost 2022; 20(1): 149-156.

https://doi.org/10.1111/jth.15572

Kotlyar A, Grechukhina O, Chen A. Vertical transmission of COVID-19: a systematic review and meta-analysis. Am J Obstet Gynecol 2021; 224(1): 35-53.e3.

https://doi.org/10.1016/j.ajog.2020.07.049

Gernsheimer T, James AH, Stasi R. How I treat throm-bocytopenia in pregnancy. Blood. 2013; 121(1): 38-47.

https://doi.org/10.1182/blood-2012-08-448944

Bennett C, Chambers LM, Son J, Goje O. Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination. J Obstet Gynaecol Res 2021; 47(11): 4077-4080. https://doi.org/10.1111/jog.14978

Mousavi SA, Rad S, Rostami T, Rostami M, Mousavi SA, Mirhoseini SA, et al. Hematologic predictors of mortality in hospitalized patients with COVID-19: a comparative study. Hematology 2020; 25(1): 383-8.

https://doi.org/10.1080/16078454.2020.1833435

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18(5): 1094-1099.

https://doi.org/10.1111/jth.14817

Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020; 506: 145-148.

https://doi.org/10.1016/j.cca.2020.03.022

Allotey J, Fernandez S, Bonet M, Stallings E, Yap M, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020; 370.

https://doi.org/10.1136/bmj.m3320

Pathirathna ML, Samarasekara BPP, Dasanayake TS, Saravanakumar P, Weerasekara I. Adverse Perinatal Outcomes in COVID-19 Infected Pregnant Women: A Systematic Review and Meta-Analysis. Healthcare 2022; 10(2): 203.

https://doi.org/10.3390/healthcare10020203

Amirian A, Pakzad R, Hasanpour V, Mirzadeh N, Abdi F. Neonatal outcome among pregnant women with COVID-19: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2022; 35(25): 9234-9248.

https://doi.org/10.1080/14767058.2021.2022648